You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Required advisory statements for medicine labels - proposed update 1
This document was released in February 2005 and comments closed on 14 March 2005. It remains on this website as a historical reference.
This document is to advise stakeholders of proposed changes to the Required Advisory Statements for Medicine Labels edition 1, dated 1 July 2004 (RASML), and to request comment from stakeholders on the changes proposed.
The proposed changes are to:
- Correct errors in the existing document; and
- Amend entries in accordance with changes to the Standard for the Uniform Scheduling of Drugs and Poisons (SUSDP).
Request to stakeholders
Stakeholders are requested to review and comment on the proposed changes. Responses should include:
- Whether or not you support the proposed changes. If you do not support a change, you may make suggestions for an alternative acceptable to you;
- An assessment of how the proposed change will impact on you. That is, what do you see as the likely benefits or costs to you (these may be financial or non-financial). If possible, please attempt to quantify these costs and benefits.